Stephen L Silvestro sold $30k of OPRX
Chief Executive Officer at OptimizeRx Corp. 1,620 shares at an average of $18.75, traded Oct 3, 2025, filed Oct 7, 2025.
Score components
- +25RoleCEO
- +5Trade size$30k at market
- 0Share of holdings soldSold 0.9% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +5.5%, 3m -25.8%, 6m -63.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-25-044543, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 3, 2025 | MOption exercise Common Stock | +6,649 | $0.00 | $0 | 190,536 | Oct 7, 2025 |
| Oct 3, 2025 | SOpen-market sale Common Stock | -1,620 | $18.75 | $30k | 188,916 | Oct 7, 2025 |
| Oct 3, 2025 | MOption exercise Restricted Stock Unitsderivative | -6,649 | $0.00 | $0 | 0 | Oct 7, 2025 |
Related signals
Other insiders at OptimizeRx Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 7Weak | OPRXsell OptimizeRx Corp | Edward Stelmakh Chief Finance & Strat Officer | $19k 1,388 shares | -1% | |
| 32Weak | OPRXsell OptimizeRx Corp | Patrick D Spangler director | $194k 11,120 shares | -20% | |
| 35Weak | OPRXbuy OptimizeRx Corp | William J Febbo CEO | $100k 20,000 shares | +3% | |
| 12Weak | OptimizeRx Corp | Marion Odence-Ford General Counsel and CCO | $61k 4,000 shares | -26% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.